Make us a preferred source
Please login to bookmark Close

Melbourne-based biopharma Telix has filed a lawsuit against Purdue Research Foundation seeking to invalidate its patent for blockbuster prostate cancer treatment Pluvicto.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au